Skip to main content

Table 4 Case reports and clinical studies with CDK4/6 inhibitors in combination with IR

From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Authors Patients Arm Toxicity Efficacy
Hans et al. [83] Metastatic breast cancer
(HR+/HER2-)
n = 5
Palbociclib + Fulvestrant + palliative IR Digestive toxicity: mucositis (grade 1 = 20%, grade 2 = 20%)
Hematological toxicity: grade 3 neutropenia = 40%, grade 3 anemia = 20%, grade 3 thrombopenia = 40%
No skin toxicity
Symptom control and pain relief (100%)
Ippolito et al. [84] Metastatic breast cancer
(HR+)
n = 16
Palbociclib or Ribociclib + palliative IR Hematological toxicity: neutropenia (grade 2 = 12.5%, grade 3 = 25%, grade 4 = 6.3%) Absent
Figura et al. [85] Brain metastatic breast cancer
(HR+)
n = 15
lesions = 42
Palbociclib or Abemaciclib + SBRT Radionecrosis (2 lesions, 5%)
No neurologic toxicity or scalp toxicity
Median OS 36.7 months
Six-month local control (88%)
Six-month distant brain control (61%)
Chowd-hary et al. [86] Metastatic breast cancer
(HR+/HER2-)
n = 16
Palbociclib + Fulvestrant or Letrozole + palliative IR Hematological toxicity: grade 1 = 87.5%, grade 2 = 12.5%
No grade 2 or higher cutaneous, neurologic, or gastrointestinal toxicity
Local control and pain relief (100%)